MAIA Biotechnology Inc. (MAIA)
1.55
0.01 (0.65%)
At close: Apr 17, 2025, 3:58 PM
1.55
-0.08%
After-hours: Apr 17, 2025, 08:00 PM EDT
Company Description
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer.
Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity.
The company was founded in 2018 and is headquartered in Chicago, Illinois.
MAIA Biotechnology Inc.
| Country | United States |
| IPO Date | Jul 28, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Dr. Vlad Vitoc M.B.A., M.D. |
Contact Details
Address: 444 West Lake Street Chicago, Illinois United States | |
| Website | https://www.MAIABiotech.com |
Stock Details
| Ticker Symbol | MAIA |
| Exchange | AMEX |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001878313 |
| CUSIP Number | 552641102 |
| ISIN Number | US5526411021 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vlad Vitoc M.B.A., M.D. | Co-Founder, President, Chief Executive Officer & Chairman of the Board of Directors |
| Dr. Sergei M. Gryaznov Ph.D. | Chief Scientific Officer |
| Jeffrey C. Himmelreich | Head of Finance and Principal Financial & Accounting Officer |
| Linda Moreira | Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 08, 2025 | 4 | Filing |
| Apr 08, 2025 | 4 | Filing |
| Apr 08, 2025 | 4 | Filing |
| Apr 08, 2025 | 4 | Filing |
| Apr 08, 2025 | 4 | Filing |
| Apr 08, 2025 | 4 | Filing |
| Apr 08, 2025 | DEFA14A | Filing |
| Apr 08, 2025 | DEF 14A | Filing |
| Apr 01, 2025 | 8-K | Current Report |
| Mar 28, 2025 | S-8 | Filing |